chartexchange

Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results

Business Wire | Nov 9, 2026 7:00 AM EST

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases, today provided corporate updates and reported financial results for the three and nine months ended September 30, 2026. Additional Stage 1/Phase 2a results show encouraging response in the full atopic dermatitis trial population In October 2026, Turn Therapeutics reported additional res

Read original article